Cefepime-taniborbactam superior to meropenem in treating complicated UTIs and acute pyelonephritis: NEJM
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-20 01:45 GMT | Update On 2024-02-20 01:45 GMT
Advertisement
Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa pose significant global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor combination with activity against these organisms.
A study published in The New England Journal of Medicine (NEJM) concluded that Cefepime-taniborbactam was more effective than meropenem in treating complicated urinary tract infections involving acute pyelonephritis and had a safety profile comparable to meropenem.
In this phase 3 trial, researchers assigned hospitalized adults with complicated UTIs to receive either cefepime-taniborbactam or meropenem for seven days, with the possibility of extending treatment for an additional seven days if bacteremia was present. The composite success rate on days 19-23 in the microbiologic intention-to-treat population determined the primary outcome. After confirming non-inferiority, a prespecified superiority analysis was conducted.
Key findings from the study are:
- Six hundred sixty-one patients underwent randomization; 436 of these were included in the microITT population.
- Patients' mean age was 56, and nearly 38 % were 65 or older.
- In the microITT population, UTI, acute pyelonephritis and bacteremia were detected in 57.8%, 42.2% and 13.1%, respectively.
- 70.6 % in cefepime–taniborbactam and 58 % in the meropenem group had composite success.
- Considering the primary outcome, Cefepime–taniborbactam was superior to meropenem with a treatment difference of 12.6 percentage points.
- Differences in treatment response were sustained at late follow-up (when Cefepime–taniborbactam had higher composite success and clinical success.
- In the Cefepime–taniborbactam and the meropenem groups, adverse events occurred in 35.5% and 29.0% of patients, respectively.
- Adverse events included headache, diarrhoea, constipation, hypertension, and nausea. The frequency of SAEs was similar for both groups.
Concluding further, Cefepime-taniborbactam demonstrated superior efficacy to meropenem in managing complicated urinary tract infections with acute pyelonephritis while exhibiting a safety profile similar to that of meropenem. The study received funding from Venatorx Pharmaceuticals.
Reference:
Florian M. Wagenlehner et al.
Cefepime–Taniborbactam in Complicated Urinary Tract Infection
N Engl J Med 2024; 390:611-622
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.